These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11706882)

  • 61. Cell-based therapies in Parkinson's disease.
    Greene P
    Curr Neurol Neurosci Rep; 2009 Jul; 9(4):292-7. PubMed ID: 19515281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hematopoietic potential of neural stem cells: plasticity versus heterogeneity.
    Shih CC; DiGiusto D; Mamelak A; Lebon T; Forman SJ
    Leuk Lymphoma; 2002 Dec; 43(12):2263-8. PubMed ID: 12613511
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stem cells as promising therapeutic options for neurological disorders.
    Yoo J; Kim HS; Hwang DY
    J Cell Biochem; 2013 Apr; 114(4):743-53. PubMed ID: 23097262
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Human embryonic stem cell research: implications from an ethical and legal standpoint.
    Trepagnier DM
    J La State Med Soc; 2000 Dec; 152(12):616-24. PubMed ID: 11191025
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Stem cells and Parkinson's disease: toward a treatment, not a cure.
    Svendsen C
    Cell Stem Cell; 2008 May; 2(5):412-3. PubMed ID: 18462691
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of stem cell-based therapies for Parkinson's disease.
    Zhu B; Caldwell M; Song B
    Int J Neurosci; 2016 Nov; 126(11):955-62. PubMed ID: 26824870
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CNS immunological modulation of neural graft rejection and survival.
    Borlongan CV; Stahl CE; Cameron DF; Saporta S; Freeman TB; Cahill DW; Sanberg PR
    Neurol Res; 1996 Aug; 18(4):297-304. PubMed ID: 8875445
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preparation, characterization, and banking of clinical-grade cells for neural transplantation: Scale up, fingerprinting, and genomic stability of stem cell lines.
    Natalwala A; Kunath T
    Prog Brain Res; 2017; 230():133-150. PubMed ID: 28552226
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adult stem cell therapy beyond haemopoietic stem cell transplantation? An update.
    Hows J
    Transpl Immunol; 2005 Aug; 14(3-4):221-3. PubMed ID: 15982566
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cell replacement therapy for Parkinson's disease: how close are we to the clinic?
    Ganz J; Lev N; Melamed E; Offen D
    Expert Rev Neurother; 2011 Sep; 11(9):1325-39. PubMed ID: 21864078
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.
    Fung RK; Kerridge IH
    Bioethics; 2013 Feb; 27(2):89-96. PubMed ID: 21726264
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The future of cell therapies in the treatment of Parkinson's disease.
    Laguna Goya R; Kuan WL; Barker RA
    Expert Opin Biol Ther; 2007 Oct; 7(10):1487-98. PubMed ID: 17916042
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pluripotent stem cells--model of embryonic development, tool for gene targeting, and basis of cell therapy.
    Prelle K; Zink N; Wolf E
    Anat Histol Embryol; 2002 Jun; 31(3):169-86. PubMed ID: 12479360
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human fetal tissue research: practice, prospects, and policy.
    Fine A
    Cell Transplant; 1994; 3(2):113-45. PubMed ID: 8012729
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Stem-cell-based strategies for the treatment of Parkinson's disease.
    Parish CL; Arenas E
    Neurodegener Dis; 2007; 4(4):339-47. PubMed ID: 17627139
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Adult neurogenesis and stem cells. Functional capacity].
    Reinoso Suárez F
    An R Acad Nac Med (Madr); 2002; 119(3):507-21; discussion 521-8. PubMed ID: 12812039
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current Developments in Cell Replacement Therapy for Parkinson's Disease.
    Guo X; Tang L; Tang X
    Neuroscience; 2021 May; 463():370-382. PubMed ID: 33774124
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Developing stem cell therapies for Parkinson's disease: waiting until the time is right.
    Barker RA
    Cell Stem Cell; 2014 Nov; 15(5):539-42. PubMed ID: 25517462
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Stem cell transplantation: a promising therapy for Parkinson's disease.
    Wang Y; Chen S; Yang D; Le WD
    J Neuroimmune Pharmacol; 2007 Sep; 2(3):243-50. PubMed ID: 18040857
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease.
    Parish CL; Parisi S; Persico MG; Arenas E; Minchiotti G
    Stem Cells; 2005 Apr; 23(4):471-6. PubMed ID: 15790767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.